SARS-CoV

CAS No.	Product Name	Inquiry
2445585-37-3	SARS-CoV-IN-4 SARS-CoV-IN-4 (compound 13) is a potent and specific inhibitor of SARS-CoV nsp14 N7-methyltransferase, with an IC50 of 0.6 μM (SARS-CoV nsp14). SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals.
2455518-33-7	X77 X77 (N-(4-tert-butylphenyl)-N-[(1R)-2-(cyclohexylamino)-2-oxo-1-(pyridin-3-yl)ethyl]-1H-imidazole-4-carboxamide) is a potent non-covalent inhibitor of the main protease of SARS-CoV-2.
2468015-78-1	Lufotrelvir Lufotrelvir is a small molecule prodrug that targets 3CLpro protease (Mpro), an enzyme used by viruses like SARS-CoV-2 to assemble and multiply. Once administered through intravenous infusion, It is cleaved into PF-00835231 to exert its antiviral effects.
2483831-63-4	Dexamethasone-4-6α-21-21-d4 Dexamethasone-4,6α,21,21-d4 is the deuterium labeled Dexamethasone-4,6α,21,21. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
2488661-53-4	NK007 NK007(S,R) is a tylophorine malate, displaying high antiviral activity against SARS-CoV-2.
249503-25-1	BCX4430 freebase BCX4430, a novel synthetic adenosine analogue, inhibits infection of distinct filoviruses in human cells. Interfering with the replication process is a well-established antiviral strategy that has been successfully exploited in developing such life-saving drugs as the nucleoside inhibitors of HIV and acyclovir for herpes simplex complex. BCX4430 may be suitable for administration by intravenous (IV), intramuscular (IM), and oral (PO) routes.
2505241-13-2	SARS-CoV-2-3CLpro-IN-3 SARS-CoV-2 3CLpro-IN-3 (Compound 3d) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities
2505241-31-4	SARS-CoV-2-3CLpro-IN-4 SARS-CoV-2 3CLpro-IN-4 (Compound 5g) is a SARS CoV-2 3CLpro inhibitor with antiviral, antibacterial and antifungal activities.
2509447-07-6	Amubarvimab
2509447-08-7	Romlusevimab
2516243-54-0	Adintrevimab
2529854-88-2	Plutavimab
2540797-21-3	Rimteravimab
254435-95-5	Alisporivir Alisporivir, also known as DEB-025, a non-immunosuppressive cyclosporine A derivative, is acyclophil ininhibitor molecule with potent anti-hepatitis C virus (HCV) activity. Treatment with alisporivir alone or combined with PEGylated IFNalpha2a reduced the viral load in patients with chronic HCV infection.
2550869-33-3	Lomtegovimab
2563866-80-6	Indinavir-sulfate-ethanolate Indinavir sulfate ethanolate (MK-639 ethanolate) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir sulfate ethanolate exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing Apoptosis. Indinavir sulfate ethanolate is also a SARS-CoV 3CLpro inhibito.
2570461-66-2	SARS-CoV-2-IN-7 SARS-CoV-2-IN-7 inhibits viral replication in SARS-CoV-2-infected Vero E6 cells, which has the potential for COVID-19 research.
2574390-27-3	MM3122 MM3122 is a selective type II transmembrane serine protease (TMPRSS2) inhibitor with an IC50 value of 0.34 nM. MM3122 effectively blocks TMPRSS2, thereby inhibiting the entry of SARS-CoV-2 and MERS-CoV into human cells.
2578319-11-4	Bebtelovimab
2599039-60-6	Ogalvibart

※ Please kindly note that our services are for research use only.